Canada - English - Health Canada

jamp pharma corporation - ticagrelor - tablet - 90mg - ticagrelor 90mg

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - ticagrelor 60mg - film coated tablet - 60 mg - active: ticagrelor 60mg excipient: calcium hydrogen phosphate magnesium stearate mannitol opadry yellow 00f520007 povidone purified water sodium starch glycolate - ticagrelor-teva, co-administered with acetylsalicylic acid (aspirin), is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke), - in patients with acute coronary syndromes (unstable angina [ua], non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]); including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg) and - in patients with a history of myocardial infarction (mi occurred at least one year ago) and a high risk of developing an atherothrombotic event.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - ticagrelor 90mg - film coated tablet - 90 mg - active: ticagrelor 90mg excipient: calcium hydrogen phosphate magnesium stearate mannitol opadry yellow 00f520007 povidone purified water sodium starch glycolate - ticagrelor-teva, co-administered with acetylsalicylic acid (aspirin), is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke), - in patients with acute coronary syndromes (unstable angina [ua], non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]); including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg) and - in patients with a history of myocardial infarction (mi occurred at least one year ago) and a high risk of developing an atherothrombotic event.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - ticagrelor 90mg - film coated tablet - 90 mg - active: ticagrelor 90mg excipient: calcium hydrogen phosphate dihydrate croscarmellose sodium hypromellose magnesium stearate mannitol microcrystalline cellulose opadry yellow 32k520044 - ticagrelor mylan, co-administered with acetylsalicylic acid (aspirin), is indicated for the prevention of atherothrombotic events in patients with acute coronary syndromes (unstable angina [ua], non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]); including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg).

Malta - English - Medicines Authority

abdi farma gmbh donnersbergstraße 4 64646 heppenheim, , germany - film-coated tablet - ticagrelor 60 mg - antithrombotic agents

Malta - English - Medicines Authority

abdi farma gmbh donnersbergstraße 4 64646 heppenheim, , germany - film-coated tablet - ticagrelor 90 mg - antithrombotic agents

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - ticagrelor (unii: glh0314rvc) (ticagrelor - unii:glh0314rvc) - ticagrelor 90 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - ticagrelor, quantity: 90 mg - tablet, dispersible - excipient ingredients: mannitol; microcrystalline cellulose; crospovidone; xylitol; calcium hydrogen phosphate; sodium stearylfumarate; hyprolose; colloidal anhydrous silica - brilinta, in combination with aspirin, is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke) in adult patients with acute coronary syndromes (unstable angina [ua], non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]) including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg).

Israel - English - Ministry of Health

astrazeneca (israel) ltd - ticagrelor - film coated tablets - ticagrelor 60 mg - ticagrelor - brilinta, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with - acute coronary syndromes (acs) or- a history of myocardial infarction (mi) and a high risk of developing an atherothrombotic event (see sections 4.2 and 5.1).limitations of use: 90 mg twice daily during the first year after an acs event followed by 60 mg twice daily for additional 2 years.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ticagrelor, quantity: 90 mg - tablet, film coated - excipient ingredients: sodium stearylfumarate; sodium lauryl sulfate; calcium hydrogen phosphate dihydrate; iron oxide yellow; titanium dioxide; pregelatinised maize starch; mannitol; purified talc; glyceryl caprylate/caprate; polyvinyl alcohol; maize starch - ticagrelor sandoz, in combination with aspirin, is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke) in adult patients with acute coronary syndromes (unstable angina [ua], non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]) including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg).